Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis

Phase 2 Terminated 47 enrolled Aclaris Therapeutics, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase 2a study to investigate the efficacy, safety, tolerability, PK, and PD of ATI-450 versus placebo in patients with moderate to severe psoriatic arthritis.

Timeline

Start: 2022-07-12
Primary completion: 2023-12-06
Completion: 2024-01-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Zunsemetinib	Small molecule	50 mg	Oral

Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis

Summary

Timeline

Drugs

Indications